Petra Steinacker

TL;DR: Neurofilaments in CSF have a high relevance for the differential diagnosis of MNDs and should be included in the diagnostic work-up of patients and their value as prognostic markers should be investigated further.

TL;DR: CSF TDP-43 levels in CSF might aid in characterizing subgroups of patients across the ALS and FTLD disease spectrum, and although there is no evidence of pathologically altered Tarpa DNA-binding protein 43 proteins inCSF, TDP’s levels might aid the characterizing of patients within these subgroups.

TL;DR: Low levels of Aβ1-42 in CSF do not exclude a diagnosis of CJD and can occur without β-amyloid plaque formation in the brain, however the underlying mechanism of this phenomenon must be elucidated.

TL;DR: In this article, the authors found that neurofilaments are elevated in cerebrospinal fluid (CSF) and serum of amyotrophic lateral sclerosis (ALS) patients.

TL;DR: Serum GFAP correlated with the Mini-Mental State Examination score and might be a follow-up marker in clinical trials and the first blood biomarker in the differential diagnosis of AD and bvFTD.